Investors News Releases News Releases Investor Relations Investor Relations News Releases Presentations & Events Common Stock Information Stock Quote & Chart Analyst Coverage SEC Filings Corporate Governance Overview Board of Directors Committee Composition Management Team Annual Reports News Releases Year None202320222021202020192018201720162015201420132012201120102009200820072006 Nov 30 2023 Cyclacel Regains Compliance With Nasdaq Listing Rule Following Filing of Its Form 10-Q With the SEC Nov 28 2023 Cyclacel Receives Notification of Deficiency From Nasdaq Regarding Timely Filing of Quarterly Report on Form 10-Q Nov 13 2023 Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update Nov 07 2023 Cyclacel Pharmaceuticals to Release Third Quarter 2023 Financial Results Aug 09 2023 Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update Aug 03 2023 Cyclacel Pharmaceuticals to Release Second Quarter 2023 Financial Results May 11 2023 Cyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update May 04 2023 Cyclacel Pharmaceuticals to Release First Quarter 2023 Financial Results May 03 2023 Cyclacel Pharmaceuticals Announces Receipt of $4.7 Million R&D Tax Credit Mar 07 2023 Cyclacel Pharmaceuticals to Participate in March Investor Conferences Mar 06 2023 Cyclacel Pharmaceuticals Reports Fourth Quarter And Full Year 2022 Financial Results And Provides Business Update Feb 27 2023 Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2022 Financial Results Jan 30 2023 Cyclacel Pharmaceuticals to Participate in the 2023 BIO CEO & Investor Conference Jan 05 2023 Cyclacel Pharmaceuticals Reviews 2022 Achievements and Announces Key Business Objectives for 2023 Dec 15 2022 Cyclacel Pharmaceuticals to Present at Biotech Showcase and Participate in a Corporate Access Event During the J.P. Morgan Healthcare Conference in January 2023 Nov 09 2022 Cyclacel Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update Nov 03 2022 Cyclacel Pharmaceuticals to Release Third Quarter 2022 Financial Results Oct 26 2022 Cyclacel Reports Preliminary Data From Its Phase 1/2 Clinical Trial of Oral Fadraciclib in Patients With Solid Tumors and Lymphoma at ENA 2022 Oct 24 2022 Cyclacel Hosting Research & Development Day Oct 13 2022 Cyclacel Pharmaceuticals To Present Preliminary Data From The Phase 1/2 Clinical Trial Of Oral Fadraciclib At The 34th EORTC-NCI-AACR Symposium Sep 21 2022 Cyclacel Pharmaceuticals to Present at the Ladenburg Thalmann 2022 Healthcare Conference Aug 10 2022 Cyclacel Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update Aug 03 2022 Cyclacel Pharmaceuticals to Release Second Quarter 2022 Financial Results Jun 30 2022 Cyclacel Pharmaceuticals Achieves Key Business Objectives in First Half of 2022 and Continues to Advance Clinical Pipeline Jun 22 2022 Cyclacel Pharmaceuticals Announces That Kenneth M. Ferguson, Ph.D. Was Elected to Its Board of Directors Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last » Toolkit Email AlertsRSS FeedsPrint Page
News Releases Year None202320222021202020192018201720162015201420132012201120102009200820072006 Nov 30 2023 Cyclacel Regains Compliance With Nasdaq Listing Rule Following Filing of Its Form 10-Q With the SEC Nov 28 2023 Cyclacel Receives Notification of Deficiency From Nasdaq Regarding Timely Filing of Quarterly Report on Form 10-Q Nov 13 2023 Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update Nov 07 2023 Cyclacel Pharmaceuticals to Release Third Quarter 2023 Financial Results Aug 09 2023 Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update Aug 03 2023 Cyclacel Pharmaceuticals to Release Second Quarter 2023 Financial Results May 11 2023 Cyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update May 04 2023 Cyclacel Pharmaceuticals to Release First Quarter 2023 Financial Results May 03 2023 Cyclacel Pharmaceuticals Announces Receipt of $4.7 Million R&D Tax Credit Mar 07 2023 Cyclacel Pharmaceuticals to Participate in March Investor Conferences Mar 06 2023 Cyclacel Pharmaceuticals Reports Fourth Quarter And Full Year 2022 Financial Results And Provides Business Update Feb 27 2023 Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2022 Financial Results Jan 30 2023 Cyclacel Pharmaceuticals to Participate in the 2023 BIO CEO & Investor Conference Jan 05 2023 Cyclacel Pharmaceuticals Reviews 2022 Achievements and Announces Key Business Objectives for 2023 Dec 15 2022 Cyclacel Pharmaceuticals to Present at Biotech Showcase and Participate in a Corporate Access Event During the J.P. Morgan Healthcare Conference in January 2023 Nov 09 2022 Cyclacel Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update Nov 03 2022 Cyclacel Pharmaceuticals to Release Third Quarter 2022 Financial Results Oct 26 2022 Cyclacel Reports Preliminary Data From Its Phase 1/2 Clinical Trial of Oral Fadraciclib in Patients With Solid Tumors and Lymphoma at ENA 2022 Oct 24 2022 Cyclacel Hosting Research & Development Day Oct 13 2022 Cyclacel Pharmaceuticals To Present Preliminary Data From The Phase 1/2 Clinical Trial Of Oral Fadraciclib At The 34th EORTC-NCI-AACR Symposium Sep 21 2022 Cyclacel Pharmaceuticals to Present at the Ladenburg Thalmann 2022 Healthcare Conference Aug 10 2022 Cyclacel Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update Aug 03 2022 Cyclacel Pharmaceuticals to Release Second Quarter 2022 Financial Results Jun 30 2022 Cyclacel Pharmaceuticals Achieves Key Business Objectives in First Half of 2022 and Continues to Advance Clinical Pipeline Jun 22 2022 Cyclacel Pharmaceuticals Announces That Kenneth M. Ferguson, Ph.D. Was Elected to Its Board of Directors Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last »
Nov 30 2023 Cyclacel Regains Compliance With Nasdaq Listing Rule Following Filing of Its Form 10-Q With the SEC
Nov 28 2023 Cyclacel Receives Notification of Deficiency From Nasdaq Regarding Timely Filing of Quarterly Report on Form 10-Q
Nov 13 2023 Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update
Aug 09 2023 Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update
May 11 2023 Cyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update
Mar 06 2023 Cyclacel Pharmaceuticals Reports Fourth Quarter And Full Year 2022 Financial Results And Provides Business Update
Jan 05 2023 Cyclacel Pharmaceuticals Reviews 2022 Achievements and Announces Key Business Objectives for 2023
Dec 15 2022 Cyclacel Pharmaceuticals to Present at Biotech Showcase and Participate in a Corporate Access Event During the J.P. Morgan Healthcare Conference in January 2023
Nov 09 2022 Cyclacel Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update
Oct 26 2022 Cyclacel Reports Preliminary Data From Its Phase 1/2 Clinical Trial of Oral Fadraciclib in Patients With Solid Tumors and Lymphoma at ENA 2022
Oct 13 2022 Cyclacel Pharmaceuticals To Present Preliminary Data From The Phase 1/2 Clinical Trial Of Oral Fadraciclib At The 34th EORTC-NCI-AACR Symposium
Aug 10 2022 Cyclacel Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
Jun 30 2022 Cyclacel Pharmaceuticals Achieves Key Business Objectives in First Half of 2022 and Continues to Advance Clinical Pipeline
Jun 22 2022 Cyclacel Pharmaceuticals Announces That Kenneth M. Ferguson, Ph.D. Was Elected to Its Board of Directors
